Cooperative Agreement UG3HL180990
Award Date 8/15/25
Completion Date 7/31/26
Dollars Obligated $2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Stanford, CA 94305, USA
Similar Awards
- This $936,858 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a Phase 2 clinical trial to evaluate the safety and efficacy of the drug tiprelestat (recombinant human elafin) for the treatment of pulmonary arterial hypertension (PAH). The clinical trial, known as the ATHENA trial, will be a multi-center, randomized, double-blind, placebo-controlled study to assess the impact of tiprelestat on pulmonary...
- The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $2,442,173 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) to identify genes and pathways that influence the risk of vascular diseases such as coronary artery disease (CAD) and pulmonary arterial hypertension (PAH). The 5-year award, effective August 15, 2025, will leverage innovative CRISPR genomics approaches to characterize gene...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $245,626 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Johns Hopkins University. The grant, with a project period from February 1, 2025 to January 31, 2027, will fund research to validate lipidomic signatures associated with right ventricular and pulmonary vascular dysfunction in pulmonary arterial hypertension (PAH). The project aims to replicate the researchers' preliminary findings on...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to investigate the role of the kynurenine pathway metabolism in pulmonary arterial hypertension (PAH). The $514,484 award to The Johns Hopkins University will fund a 5-year research project to establish a prospective observational cohort of PAH patients and measure longitudinal changes in kynurenine pathway metabolites and...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,505,110 to The Leland Stanford Junior University to conduct research on human pulmonary neuroendocrine cells (PNECs) and their stem cells. The key objectives are to map the innervation and molecular subtypes of human PNECs, identify their functional subsets, and characterize the cellular and molecular features of PNEC stem cells and their niches. This...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $161,568.00 to The Leland Stanford Junior University (Stanford University) to conduct research aimed at disaggregating and spatially profiling early-stage lung fibrosis microenvironments. The overarching goal is to utilize spatial biology and biomaterial modeling techniques to uncover the cellular and molecular drivers of early fibrogenesis in interstitial...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,385,536 to Rhode Island Hospital to conduct research on pulmonary arterial hypertension (PAH). The goal is to characterize endothelial cell (EC) dysfunction in PAH, with a focus on understanding the role of anoikis resistance - abnormal programmed cell death triggered by cell detachment from the vessel wall. The research will leverage a "cell...
- The National Heart, Lung, and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $1,196,948 Cooperative Agreement to The Leland Stanford Junior University (Stanford University) on September 5, 2025. The award supports the "Women's Aneurysm Research: Repair Immediately or Routine Surveillance (WARRIORS) Trial", an international, randomized controlled trial designed to determine whether women aged 50+ with small (4.0-5.4 cm)...